Method of producing human monoclonal antibodies and kit therefor
First Claim
1. In an improved method for in vitro immunization of lymphocytes for use in production of human monoclonal antibodies, the improvement comprising:
- exposing human peripheral blood lymphocytes to a lysomotrophic agent selected from the group consisting of L-leucine-O-methyl ester, L-glutamic acid dimethyl ester and L-leucyl-L-leucine-O-methyl ester to produce treated human lymphocytes; and
exposing said treated human lymphocytes to an antigen to activate lymphocytes wherein said treated, activated lymphocytes produce antibody which specifically binds said antigen.
0 Assignments
0 Petitions
Accused Products
Abstract
A method for the removal of, for in vitro immunization, undesired cells from human lymphocyte containing cell populations is disclosed. For the method, use is made of lysosomotropic agents which are caused to act in vitro on human lymphocyte containing cell populations.
Also disclosed is a method in the in vitro immunization of lymphocytes for use in the production of human monoclonal antibodies. In this method, lysosomotropic agents are caused to act in vitro on human lymphocyte containing cell populations for removing cell populations having a negative effect on the in vitro immunization, whereupon the lymphocytes are in vitro immunized antigen-specifically and immortalized.
Finally, a kit for in vitro immunization of lymphocytes for use in the production of human monoclonal antibodies is disclosed. The kit comprises as active constituents a container containing lymphokines and a container containing lysosomotropic agents.
-
Citations
11 Claims
-
1. In an improved method for in vitro immunization of lymphocytes for use in production of human monoclonal antibodies, the improvement comprising:
-
exposing human peripheral blood lymphocytes to a lysomotrophic agent selected from the group consisting of L-leucine-O-methyl ester, L-glutamic acid dimethyl ester and L-leucyl-L-leucine-O-methyl ester to produce treated human lymphocytes; and exposing said treated human lymphocytes to an antigen to activate lymphocytes wherein said treated, activated lymphocytes produce antibody which specifically binds said antigen. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
Specification